Loading
waveLINE-003 tests a ROR1-directed ADC added to standard salvage chemotherapy.
waveLINE-003, trial NCT05139017 sponsored by Merck, is a phase 2/3 trial testing the ROR1-directed antibody-drug conjugate zilovertamab vedotin, also known as MK-2140, added to rituximab, gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma after at least one line, in transplant-ineligible or post-transplant patients. A companion frontline trial, waveLINE-010, tests the drug with R-CHP. OnCo links it to lymphoma, ROR1 as a target and zilovertamab vedotin. It is recruiting with no results, and whether ROR1, a target without an approved drug, can be exploited safely with an ADC is the question it exists to answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma.
Shares Zilovertamab vedotin, Merck & Co. (MSD).
Shares ROR1, Diffuse large B-cell lymphoma.
Shares ROR1, Zilovertamab vedotin, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/